Pathologist's health‐care value in the triage of Oncotype DX® testing: a value‐based pathology study of tumour biology with outcomes. Issue 4 (6th August 2018)

• Record Type: Journal Article
• Authors: Dabbs, David J; Clark, Beth Z; Serdy, Kate; Onisko, Agnieszka; Brufsky, Adam M; Smalley, Sherie; Perkins, Stephen; Bhargava, Rohit
• Is Part Of: Histopathology. Volume 73:Issue 4(2019)
• Page Start: 692
• Page End: 700
• Publication Date: 2018-08-06
• Subjects: oncotype Dx -- pathologist -- value; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.13690
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: Pathologists provide expert tissue assessment of breast cancer, yet their value to guide the appropriate use of breast cancer gene expression profile tests (GEPT) is underutilised. The specific aims of this study are to report morpho‐immunohistological characteristics of breast tumours with Oncotype DX ® (ODx) recurrence scores (RS) of 10 or fewer (ultra‐low risk) and 25 or fewer (low risk) in order to determine if pathologists can identify prospectively patient tumours that do not require ODx testing. Methods and results: Oncotype DX ® cases with RS < 10 from 2005 to 2010 comprised 441 of 2594 (17%) of clinical cases; this cohort had 5 years' follow‐up and was treated with endocrine therapy alone. Tumours were analysed for tumour type, Nottingham grade, mitosis score (MS) semi‐quantitative (H‐score) hormone receptor content and Magee equation 3. Knowledge derived from this data set was used to develop algorithms in order to identify prospectively tumours with RS of 10 or fewer or 25 or fewer. Thirty‐four per cent of tumours were low‐grade special types, while the remainder were enriched with high hormone receptor content with MS of 1. These algorithmic selection criteria identified correctly all patient cases below the chemotherapy cut‐point, i.e. RS < 25, indicating that these oncotype test orders were an unnecessary cost. Conclusions: This unique study demonstrates that (i) pathologists add great value to triage breast cancer for GEPT; and (ii) can identify prospectively low‐grade tumour biology with high sensitivity and high specificity for those cases which do not require chemotherapy (RS < 25) using MS and hormone receptor content.